18:59 , Nov 3, 2017 |  BC Week In Review  |  Financial News

Asterias raises $10.4M in registered direct offering

On Oct. 19, Asterias Biotherapeutics Inc. (NYSE-M:AST) closed a registered direct offering led by Chardan, raising $10.4 million through the sale of 4 million shares at $2.60. The company said it will use the funds...
19:58 , May 5, 2017 |  BC Week In Review  |  Clinical News

DMC recommends continuation of Ph I/IIa of AST-OPC1 for SCI

Asterias Biotherapeutics Inc. (NYSE-M:AST) said a DMC recommended enrollment continuation of the 10 and 20 million cell cohorts of AST-OPC1 in the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI). The open-label,...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

AST-OPC1: Additional Phase I/IIa data

Data from 5 patients with a complete cervical SCI who received a single injection of 10 million cells of AST-OPC1 in the open-label, dose-escalation, U.S. Phase I/IIa SCiStar trial showed that all 5 patients achieved...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

AST-OPC1: Phase I/IIa data

Researchers at Keck Medicine of the University of Southern California reported data from 1 patient with a cervical SCI in the open-label, dose-escalation, U.S. Phase I/IIa SCiStar trial showing that a single injection of 10...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

AST-OPC1: Phase I/IIa ongoing

Asterias said a DMC recommended continuation to the third and highest dose cohort in the open-label, U.S. Phase I/IIa SCiStar trial evaluating single injections of 2 million or 10 million cells of AST-OPC1 and 2...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

AST-OPC1: Phase I/IIa started

Asterias began an open-label, dose-escalation, U.S. Phase I/IIa trial to evaluate single injections of 2 million or 10 million cells of AST-OPC1 and 2 injections of 10 million cells of AST-OPC1 in about 13 patients...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

BioTime, Sangamo, Beckman Research Institute at City of Hope, California Institute for Regenerative Medicine gene/cell therapy news

CIRM awarded a $14.3 million grant to BioTime's Asterias Biotherapeutics Inc. subsidiary to develop oligodendrocyte progenitor cells ( AST-OPC1 ) to treat severe spinal cord injuries. Asterias gained the program through its 2013 acquisition of...